Biondo Investment Advisors LLC Purchases 16,245 Shares of Krystal Biotech, Inc. $KRYS

Biondo Investment Advisors LLC raised its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 31.3% during the 4th quarter, HoldingsChannel reports. The fund owned 68,130 shares of the company’s stock after buying an additional 16,245 shares during the quarter. Krystal Biotech comprises about 2.0% of Biondo Investment Advisors LLC’s portfolio, making the stock its 14th largest holding. Biondo Investment Advisors LLC’s holdings in Krystal Biotech were worth $16,797,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of KRYS. Soleus Capital Management L.P. lifted its stake in Krystal Biotech by 108.9% in the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after acquiring an additional 481,200 shares in the last quarter. Norges Bank acquired a new position in shares of Krystal Biotech during the 4th quarter worth approximately $70,159,000. William Blair Investment Management LLC increased its position in shares of Krystal Biotech by 152.1% during the 4th quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock worth $92,783,000 after purchasing an additional 227,038 shares during the last quarter. UBS Group AG increased its position in shares of Krystal Biotech by 970.8% during the 4th quarter. UBS Group AG now owns 159,595 shares of the company’s stock worth $39,347,000 after purchasing an additional 177,922 shares during the last quarter. Finally, Millennium Management LLC increased its position in shares of Krystal Biotech by 1,083.8% during the 3rd quarter. Millennium Management LLC now owns 148,713 shares of the company’s stock worth $26,252,000 after purchasing an additional 136,151 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Insiders Place Their Bets

In related news, EVP John Charles Thomas sold 642 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $302.03, for a total value of $193,903.26. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the sale, the insider owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by corporate insiders.

Krystal Biotech Trading Down 1.1%

KRYS opened at $317.97 on Friday. Krystal Biotech, Inc. has a 1-year low of $127.99 and a 1-year high of $331.49. The stock’s fifty day simple moving average is $288.44 and its 200 day simple moving average is $267.89. The stock has a market cap of $9.37 billion, a PE ratio of 42.51 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The business had revenue of $116.36 million for the quarter, compared to analysts’ expectations of $112.11 million. Equities analysts forecast that Krystal Biotech, Inc. will post 7.83 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on KRYS. Chardan Capital boosted their target price on shares of Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Wolfe Research assumed coverage on shares of Krystal Biotech in a research report on Friday, March 27th. They set a “peer perform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $310.00 price target on shares of Krystal Biotech in a research report on Monday, June 1st. Evercore reaffirmed an “outperform” rating and set a $300.00 price target on shares of Krystal Biotech in a research report on Tuesday, May 5th. Finally, Wall Street Zen raised shares of Krystal Biotech from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Ten equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Krystal Biotech presently has a consensus rating of “Moderate Buy” and an average price target of $324.11.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.